ArticleGut microbes2026
The role of gut microbes in production of aromatic carboxaldehydes.
Article in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Gut microbes play an important role in maintaining our health through the alteration of available nutrients and by the production of small molecules/metabolites. Indole-3-carboxaldehyde (I3A) is an aromatic carboxaldehyde (ArA) synthesized by gut microbes from the aromatic amino acid tryptophan, and has been mechanistically linked to antitumor activity, intestinal homeostasis, and metabolic syndrome. However, the capacity of gut microbes to produce other ArAs and their associations with host health remains largely unexplored due to a lack of methods for their detection and quantification. A stable isotope dilution mass spectrometry method for quantifying ArAs from all four aromatic amino acids (benzaldehyde (BA), 4-hydroxybenzaldehyde (4HBA), and 4-imidazolecarboxaldehyde (4IA) in addition to I3A) based on derivatization with 3-methoxyphenylhydrazine was developed and validated. Fecal levels of I3A and 4HBA were reduced in both human and mouse feces after a cocktail of nonabsorbable antibiotics depleted the gut microbiota, while the same treatment reduced BA in humans and 4IA in mice. Further, we identified multiple commensals with the capacity to produce selected ArAs in culture and showed that individuals with Crohn's disease, but not in those with ulcerative colitis, have lower fecal levels of I3A and 4HBA, relative to non-inflammatory bowel disease controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.